We fund translational research to move knowledge as quickly as possible from basic discovery to treatment of patients.
Since 2002, LUNGevity has invested in 200 research projects at 69 institutions in 24 states and the District of Columbia, for a total of $55,743,471.02.
Funded equally by LUNGevity Foundation and American Lung Association National Office
Cancer cells develop resistance to chemotherapy drugs by 1) making proteins that neutralize the effects of chemotherapy (through a protein called Bcl-2) and 2) developing pumping systems that expel the drugs out of the cells (through a protein called MRP). Dr. Minko is studying how stopping the Bcl2 and MRP proteins will make lung cancer cells more sensitive to chemotherapy drugs.
Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians
Bexarotene is a synthetic form of retinoid acid (Vitamin A) that has the potential for use in lung cancer chemoprevention. Dr. Petty is conducting a clinical trial with a treatment combination of bexarotene and erlotinib (Tarceva) in EGFR-positive patients who have metastatic non-small cell lung cancer (NSCLC). He is also evaluating biomarkers that will predict response to the combination regimen.
Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians
Tests that improve the ability to detect tumors at their earliest stages have the potential to reduce lung cancer mortality. Dr. Doerr developed three fluorescence in situ hybridization (FISH) probe sets for the detection of lung cancer in cell specimens. His research is assessing the reliability of these probe sets and routine cell examination for the detection of lung cancer in cell specimens obtained from bronchoscopy.
Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians
Surgery is often recommended for patients who have localized lung cancer. Dr. Bogolioubov is analyzing how fast lung cancer comes back after surgery to remove the primary tumor. He is also evaluating the role of chest CT radiography for post-operative follow-up.
